Search LGNXZ
LIGAND PHARMACEUTICALS INC
Nasdaq, OTC, OTC, OTC, OTC · CIK 886163
Last close0
Daily change+0.00 (60.71%)
10 Years gain+125.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
LGNXZ · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
57.8Momentum
100.0Acceleration
100.0Confidence
75.0Annual Revenue17
Quarterly Revenue69
Annual CFO17
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.2 / 25
Quality15.6 / 25
Capital Efficiency6.6 / 20
Balance Sheet12.6 / 15
Shareholder Economics0.8 / 10
Forward Indicators5.0 / 5
Signals
Operating leverageOperating margin improved by 61.0679 percentage points.
ROIC expansionROIC improved by 16.8104 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 13.7877%.
Key Metrics
Revenue Growth TTM64.16%OK
Revenue CAGR 3Y10.96%OK
Gross Marginn/aMISSING
Operating Margin32.08%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC9.51%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y13.79%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $268.09M | n/a | $41.00M | $49.36M | $48.91M | n/a | 15.29% | 18.24% | 7.48% | 20.29M |
| 2025 FY Dec 31, 2024 | $167.13M | n/a | -$22.61M | $97.05M | $95.23M | n/a | -13.53% | 56.98% | -2.66% | 18.29M |
| 2025 FY Dec 31, 2023 | $131.31M | n/a | $11.94M | $49.58M | $46.06M | n/a | 9.09% | 35.07% | 2.2% | 17.76M |
| 2024 FY Dec 31, 2022 | $196.25M | n/a | $3.04M | $137.85M | $119.93M | n/a | 1.55% | 61.11% | 0.46% | 16.87M |
| 2023 FY Dec 31, 2021 | $241.54M | n/a | $103.85M | $78.80M | $70.04M | n/a | 42.99% | 29% | 25.15% | 17.25M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $278.50M | sum latest 4 fiscal quarters Revenue | OK | 0000886163-26-000044, 0000886163-25-000063 |
| Revenue Growth TTM | 64.16% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000886163-26-000044, 0000886163-25-000063 |
| Revenue CAGR 3Y | 10.96% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000886163-26-000006 |
| Revenue CAGR 5Y | 10.39% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000886163-26-000006 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000886163-26-000044, 0000886163-25-000063 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | 32.08% | Operating Income / Revenue | OK | 0000886163-26-000044, 0000886163-25-000063 |
| ROIC | 9.51% | NOPAT / Average Invested Capital | OK | 0000886163-26-000044, 0000886163-25-000063 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000886163-26-000044 |
| Current Ratio | 31.18x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.21x | (Cash + Short-term Investments) / Total Debt | OK | 0000886163-26-000044 |
| Revenue per Diluted Share | $12.75 | Revenue / Diluted Shares | OK | 0000886163-26-000044, 0000886163-25-000063 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |